327 related articles for article (PubMed ID: 29912998)
1. Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.
Frias JP
J Fam Pract; 2018 Jun; 67(6 suppl):S25-S34. PubMed ID: 29912998
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
3. Clinical Efficacy of Once-weekly Glucagonlike Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.
Bailey TS
J Fam Pract; 2018 Jun; 67(6 suppl):S14-S24. PubMed ID: 29912997
[TBL] [Abstract][Full Text] [Related]
4. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes.
Trujillo J
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):43-60. PubMed ID: 32910487
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes.
Unni S; Wittbrodt E; Ma J; Schauerhamer M; Hurd J; Ruiz-Negrón N; McAdam-Marx C
Diabetes Obes Metab; 2018 Feb; 20(2):468-473. PubMed ID: 28862808
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials.
Xue X; Ren Z; Zhang A; Yang Q; Zhang W; Liu F
Int J Clin Pract; 2016 Aug; 70(8):649-56. PubMed ID: 27456750
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Goldman JD
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
[TBL] [Abstract][Full Text] [Related]
9. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Patel D
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Karagiannis T; Liakos A; Bekiari E; Athanasiadou E; Paschos P; Vasilakou D; Mainou M; Rika M; Boura P; Matthews DR; Tsapas A
Diabetes Obes Metab; 2015 Nov; 17(11):1065-74. PubMed ID: 26395850
[TBL] [Abstract][Full Text] [Related]
11. Dulaglutide for the treatment of type 2 diabetes.
Scheen AJ
Expert Opin Biol Ther; 2017 Apr; 17(4):485-496. PubMed ID: 28274140
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.
Kuritzky L; Umpierrez G; Ekoé JM; Mancillas-Adame L; Landó LF
Postgrad Med; 2014 Oct; 126(6):60-72. PubMed ID: 25414935
[TBL] [Abstract][Full Text] [Related]
13. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL
Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121
[TBL] [Abstract][Full Text] [Related]
14. Once-weekly glucagon-like peptide 1 receptor agonists.
Kalra S; Gupta Y
J Pak Med Assoc; 2015 Jul; 65(7):796-8. PubMed ID: 26160096
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
Wysham C; Blevins T; Arakaki R; Colon G; Garcia P; Atisso C; Kuhstoss D; Lakshmanan M
Diabetes Care; 2014 Aug; 37(8):2159-67. PubMed ID: 24879836
[TBL] [Abstract][Full Text] [Related]
16. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Nauck MA; Quast DR; Wefers J; Meier JJ
Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
[TBL] [Abstract][Full Text] [Related]
17. Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists.
Handelsman Y; Wyne K; Cannon A; Shannon M; Schneider D
J Manag Care Spec Pharm; 2018 Sep; 24(9-a Suppl):S14-S29. PubMed ID: 30156445
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella R; Pechtner V; Corcos A; Consoli A
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
[TBL] [Abstract][Full Text] [Related]
19. An Overview of the Burden of Illness and the Role of Once-Weekly Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Type 2 Diabetes.
Brunton SA
J Fam Pract; 2018 Jun; 67(6 suppl):S3-S7. PubMed ID: 29912995
[TBL] [Abstract][Full Text] [Related]
20. GLP-1 Agonists in Type 1 Diabetes Mellitus.
Janzen KM; Steuber TD; Nisly SA
Ann Pharmacother; 2016 Aug; 50(8):656-65. PubMed ID: 27252246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]